OneMedNet Corp provides healthcare data and software solutions focused on regulatory-grade, AI-ready real-world data for life sciences, medical device, research, and AI customers. Company news commonly centers on the OneMedNet iRWD™ platform, its Palantir Foundry-powered search and data access capabilities, and the commercialization of subscription-based real-world data products.
Recurring developments include platform launches, bookings and revenue updates, data licensing agreements, and collaborations that expand disease-specific and multimodal datasets. Recent company updates have discussed oncology, autoimmune, neurotechnology, medical imaging, electronic health records, longitudinal patient data, cohort discovery, and real-world evidence generation.
OneMedNet (ONMD) signed a seven-figure, multiyear data agreement with an AI-enabled precision medicine company that is its tenth channel partner.
The customer intends to use de-identified clinical data delivered through OneMedNet’s iRWD platform to train clinical and diagnostic AI models and create a licensable dataset combining its molecular data with OneMedNet’s imaging and clinical records over time. OneMedNet earns incremental annual sublicensing revenue on each end-customer license, in addition to the initial data license. The agreement includes an option to expand data volume and contract value. OneMedNet retains source-data rights; end customers may not relicense or resell the underlying OneMedNet data.
OneMedNet (ONMD) will implement a 1-for-10 reverse split of its common shares, effective September 29, 2026.
The split will combine every 10 outstanding shares into one. Outstanding shares will fall from approximately 59,286,450 as of September 24, 2026, to approximately 5,928,645. The authorized share count will not change. Stockholders approved the split on September 18, and the board selected the final ratio. OneMedNet says the split is intended to meet the Nasdaq Capital Market’s minimum bid price requirement for continued listing and broaden investor interest. Split-adjusted trading is expected to begin September 29 under ONMD, with CUSIP number 68270C 202.
Atropos Health (partnering with ONMD) announced a major expansion of its federated Atropos Evidence™ Network through deeper collaborations with Norstella and Arcadia and new data partnership agreements with OneMedNet (ONMD).
The multimodal network now comprises dozens of sources covering over 330 million U.S. patients, more than 150 million EHR records with clinical notes, scaled open and closed claims, and imaging and omics data linked to outcomes and mortality. Using privacy-first de-identification and cross-source linkage, the network supports regulatory-grade RWE, HEOR, rapid commercial analytics, and AI model training. Integrated tools can run complex temporal queries up to 50× faster and 30× more cost-effectively, all evaluated by the Real World Fitness Score® data-quality framework.
OneMedNet (ONMD) entered a multi-year strategic partnership with Atropos Health under a 3-year, subscription-based resale and license agreement. The deal embeds OneMedNet’s regulatory decision-grade, AI-driven Real-World Data directly into Atropos’ evidence-generation platform and fee arrangement that contributes to OneMedNet’s Annual Recurring Revenue (ARR). Atropos’ health system, life science, and research customers gain access to multi-modal data sourced from over 90 million patient journeys, with the option to purchase additional OneMedNet data through the Atropos platform. The companies position the integrated, imaging-rich multimodal data as a core, recurring component of Atropos’ workflows.
OneMedNet (ONMD) reported approximately $16.2 million in year-to-date 2026 bookings, a 16X increase versus the same period in 2025.
Bookings include multi-modal datasets, datasets-plus-license arrangements, and multi-year platform access licenses, with a significant portion expected to be delivered during the remainder of 2026. Around 50% of 2026 contracts are from new customers, while existing customers are expanding through reorders and follow-on engagements. Platform enhancements have improved order-fulfillment speed by about 50X, enabling the company to handle larger orders and deliver faster.
OneMedNet (Nasdaq: ONMD) announced a new agreement to supply de-identified, full-fidelity clinical Real-World Data to a leading AI-driven drug development company. Using its iRWD™ Platform, OneMedNet reports project feasibility was completed within minutes, data validation within a week, and a contract signed within three weeks of initial contact.
The customer is using OneMedNet’s first-party, regulatory decision-grade data to develop and validate AI models aimed at accelerating drug discovery and development. OneMedNet’s iRWD network now includes more than 90 million patient journeys, 270 million studies, and over 2,300 healthcare partner sites, spanning multimodal data such as radiology, cardiology, EEG, ECG, and de-identified electronic health records, with optional tokenized linkage for longitudinal analysis, according to OneMedNet.
OneMedNet (Nasdaq: ONMD) entered into an agreement valued at more than $11.5 million to supply its regulatory-grade, multi-modal, imaging-centric iRWD™ healthcare data for development and training of a foundational AI model. Data delivery is set to begin immediately and includes millions of de-identified medical images and associated clinical reports.
According to OneMedNet, this deal leverages its AI-powered iRWD™ platform and anonymized federated network, which provides live, longitudinal access to private healthcare data. The company reports commercial momentum supported by a network exceeding 90 million patient journeys, 270 million clinical studies, and more than 2,300 healthcare sites.
OneMedNet (Nasdaq: ONMD) reported more than $3 million in new 2026 bookings, already surpassing all bookings for full-year 2025. The company expects to recognize substantially all of these bookings as revenue by the end of the third quarter of 2026.
Growth reflects rising demand for its iRWD™ Platform, which provides regulatory decision-grade, multi-modal Real-World Data and now spans over 90 million patient journeys, 270 million studies, and more than 2,300 healthcare partner sites.
OneMedNet (Nasdaq: ONMD) reported major expansion of its iRWD network, now exceeding 90 million patient journeys and 270 million studies across more than 2,300 healthcare partner sites.
Patient journeys rose 12.5% in two months, and provider sites grew over 30% in under a year, with broader rare-disease and multi-modal data coverage.
OneMedNet (Nasdaq: ONMD) announced its OneMedNet iRWD™ Platform is live and fully operational on Palantir Foundry as of April 22, 2026.
The platform delivers searchable access to billions of records across 80 million patient journeys (a ~70% network increase), 251 million studies, and linkage to ~47 million tokenized patients via Datavant. Two new customers have contracted for the platform as the company pursues subscription-based annual recurring revenue.